Mark P. Labrecque

Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer

Mark P. Labrecque, Ilsa M. Coleman, Lisha G. Brown et al. · Journal of Clinical Investigation · 2019 · 439 citations · Full text

Scnpc Pdx Models, Urology, Stratifies Diverse Phenotypes +15

Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5–SN38 Antibody–drug Conjugate in Neuroendocrine Prostate Cancer

Diana C. DeLucia, Thomas M. Cardillo, Lisa S. Ang et al. · Clinical Cancer Research · 2020 · 82 citations · Full text

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program

Dae‐Hwan Kim, Duanchen Sun, William K. Storck et al. · Clinical Cancer Research · 2021 · 70 citations · Full text

Durable Response of Enzalutamide-resistant Prostate Cancer to Supraphysiological Testosterone Is Associated with a Multifaceted Growth Suppression and Impaired DNA Damage Response Transcriptomic Program in Patient-derived Xenografts

Hung‐Ming Lam, Holly M. Nguyen, Mark P. Labrecque et al. · European Urology · 2019 · 62 citations · Full text

Urology, Oncology, Patient-derived Xenografts +7

Distinct Roles for Aryl Hydrocarbon Receptor Nuclear Translocator and Ah Receptor in Estrogen-Mediated Signaling in Human Cancer Cell Lines

Mark P. Labrecque, Mandeep Takhar, Brett D. Hollingshead et al. · PLoS ONE · 2012 · 50 citations · Full text